Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).
Authors
Ann W. Silk
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Ann W. Silk, Nicole R. LeBoeuf, Guilherme Rabinowits, Igor Puzanov, Melissa Amber Burgess, Sumana Devata, Dirk Moore, James Steven Goydos, Helen X. Chen, Howard Kaufman, Andrew Zloza, Janice M. Mehnert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02978625
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr TPS219)
DOI
10.1200/JCO.2018.36.5_suppl.TPS219
Abstract #
TPS219
Poster Bd #
N4
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
An open label, multicenter, phase II study of KRT-232, an oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel cell carcinoma (MCC) who have failed treatment with anti-PD-1/L1 immunotherapy.
First Author: Glenn J. Hanna
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
T-cell lymphoma secondary to checkpoint inhibitor (CPI) used for other malignancies.
First Author: Kartik Anand
Poster
2018 ASCO Annual Meeting
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
First Author: Tian Zhang
Poster
2016 ASCO Annual Meeting
Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.
First Author: Yousef Zakharia